1 day+0.19%
Current year+3.00%
Current year 0.09
Extreme 0.09
0.11
1 year 0.09
Extreme 0.09
1.5
3 years 0.09
Extreme 0.09
10.62
5 years 0.09
Extreme 0.09
19.14
10 years 0.09
Extreme 0.09
57.39
Manager TitleAgeSince
President - 03/02/2026
Corporate Secretary - 03/02/2026
Corporate Officer/Principal - 21/01/2025
Director TitleAgeSince
Director/Board Member - 03/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
2/3/26 A Issuer sale

Director

328,690 0.2278%
2/3/26 A Issuer sale

Director

393,053 0.2724%
2/3/26 A Issuer sale

Director

328,690 0.2278%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--% - - 15.7M
-2.43%-4.38%+40.32%+55.64% 60.57B
+0.92%+4.45%+21.81%+98.49% 55.51B
+2.43%+1.43%+10.08%+74.97% 55.22B
+1.61%-3.30%+22.77%+33.16% 43.27B
-1.74%-3.02%+13.83%+93.17% 40.36B
+3.22%+4.30%+227.37%+776.49% 41.63B
-0.61%-4.08%+96.45%+85.31% 33.29B
-1.09%+0.69%+14.20%+45.26% 32.27B
-4.46%+9.98%-43.92%+320.28% 22.91B
Average -0.19%+3.38%+44.77%+175.86% 42.78B
Weighted average by Cap. +0.04%+2.15%+46.44%+161.38%
Logo Applied Therapeutics, Inc.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Employees
28
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Applied Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. APLT Stock